|The following article features coverage from the IASLC North America Conference on Lung Cancer 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Data from the GEOMETRY study were presented at the International Association for the Study of Lung Cancer (IASLC) 2019 North America Conference on Lung Cancer (NACLC 2019) in Chicago, Illinois, and showed that capmatinib was effective in treating patients with METΔex14-mutated non-small cell lung cancer (NSCLC).1
MET mutations that cause a deletion of exon 14 (METΔex14) occur in 3% to 4% of patients with NSCLC, and MET genes have been implicated in brain metastases from lung cancer. Capmatinib is a highly selective MET inhibitor that can cross the blood-brain barrier. Researchers found that the drug was successful in treating brain metastases, including in 4 patients whose brain lesions were completely resolved by treatment.
Rebecca Heist, MD, of Massachusetts General Hospital in Boston, and colleagues evaluated 97 patients enrolled in the GEOMETRY trial, a phase multicenter study of capmatinib. Patients either had not been previously treated (28 patients) or had received 1 or 2 lines of therapy (69 patients). Thirteen patients had brain metastases on enrollment; capmatinib showed treatment control in 12 of them. Seven patients with brain metastases responded to treatment intracranially, and 4 of these had a complete resolution of brain lesions. Peripheral edema, nausea, increased blood creatinine, and vomiting were the most commonly observed treatment-related adverse events across all cohorts and most adverse events were grade 1/2.
“These data confirm capmatinib to be a promising new treatment option…regardless of line of therapy,” the authors wrote, “with deep and durable responses including in patients with brain metastases, and a manageable toxicity profile.”
Read more of Cancer Therapy Advisor‘s coverage of the IASLC NACLC 2019 meeting by visiting the conference page.
- Heist R, Wolf J, Jan J-Y, et al. Capmatinib (INC280) in METΔEX14-mutated advanced NSCLC: efficacy data from the phase 2 GEOMETRY mono-1 study. Presented at: International Association for the Study of Lung Cancer (IASLC) 2019 North America Conference on Lung Cancer (NACLC 2019); October 10-12, 2019: Chicago, Illinois. Abstract OA01.07